• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    6/22/23 2:49:32 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SONN alert in real time by email
    SC 13G/A 1 mruckSONN622.htm mruckSONN622
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Sonnet BioTherapeutics Holdings, Inc.
    (Name of Issuer)
    COM NEW
    (Title of Class of Securities)
    83548R204
    (CUSIP Number)
    June 22, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 83548R204
           
    1
    NAME OF REPORTING PERSON
    Matthew J. Ruck
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [X]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Gaithersburg, Maryland, United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    1,700,000
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    c
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,700,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.18%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 83548R204
    ITEM 1(a). NAME OF ISSUER:
    Sonnet BioTherapeutics Holdings, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    100 OVERLOOK CENTER, SUITE 102, PRINCETON, NJ, 08540
    ITEM 2(a). NAME OF PERSON FILING:
    Matthew J. Ruck
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    9711 Washingtonian Blvd, Suite 550, Gaithersburg, MD 20878
    ITEM 2(c). CITIZENSHIP:
    Gaithersburg, Maryland, United States
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    COM NEW
    ITEM 2(e). CUSIP NUMBER:
    83548R204
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    1,700,000
    (b) Percent of class:
    6.18%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Matthew J. Ruck :1,700,000
    (ii) shared power to vote or to direct the vote:
    Matthew J. Ruck : 0
    (iii) sole power to dispose or direct the disposition of:
    Matthew J. Ruck :1,700,000
    (iv) shared power to dispose or to direct the disposition of:
    Matthew J. Ruck : 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 83548R204
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    June 22 2023
    Matthew J. Ruck
    By:
    /s/ Matthew J. Ruck
    Name:
    Matthew J. Ruck
    Title:
    Individual
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $SONN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SONN

    DatePrice TargetRatingAnalyst
    2/9/2022$5.00 → $2.00Buy
    BTIG
    12/20/2021$8.00 → $2.50Buy
    Chardan Capital
    12/16/2021$2.00Buy
    HC Wainwright & Co.
    9/15/2021$5.00Buy
    BTIG
    More analyst ratings

    $SONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mcandrew Stephen J claimed ownership of 446 shares (SEC Form 3)

      3 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

      2/21/25 4:05:25 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bhatt Nailesh was granted 373 shares, increasing direct ownership by 214% to 547 units (SEC Form 4)

      4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

      12/5/24 9:55:15 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Dexter Susan was granted 1,452 shares, increasing direct ownership by 760% to 1,643 units (SEC Form 4)

      4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

      12/5/24 9:55:14 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mohan Pankaj bought 34,375 shares, increasing direct ownership by 137% to 59,526 units (SEC Form 4)

      4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

      10/27/23 8:00:08 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rao Raghu bought 15,625 shares, increasing direct ownership by 1,315% to 16,813 units (SEC Form 4)

      4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

      10/27/23 8:00:10 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG reiterated coverage on Sonnet BioTherapeutics with a new price target

      BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously

      2/9/22 6:54:44 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Sonnet BioTherapeutics with a new price target

      Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously

      12/20/21 8:31:50 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Sonnet BioTherapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00

      12/16/21 8:15:32 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

      PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA. Details of the presentation are as follows: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic WindowSession: Understanding Toxicity Challenges & Improving Safety Profiles to Widen the Therapeutic WindowSpeaker: Richard Kenney, M.D., Chief Medical Officer of Sonnet Date and Time: Thursda

      5/1/25 9:00:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet Releases Virtual Investor "What This Means" Segment

      - Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team participated in a Virtual Investor "What This Means" segment.As part of the segment, Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, discussed

      4/16/25 9:10:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

      Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC), without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 5 of 15 evaluable patients (33%), with 4 continuing beyond 6 months One patient with PROC who was dosed at the MTD had a partial response (PR) by RECIST criteria (44% decrease from baseline) and >2x decrease in the CA 125 b

      4/4/25 9:00:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sonnet BioTherapeutics Holdings Inc.

      10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

      5/13/25 9:49:17 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet BioTherapeutics Holdings Inc. filed SEC Form 8-K: Other Events

      8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

      4/4/25 9:07:30 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet BioTherapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

      4/1/25 5:03:34 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

      PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends

      4/1/25 7:30:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

      PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa

      2/13/25 8:30:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

      Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan

      9/26/22 8:00:00 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

      SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

      1/2/24 4:19:28 PM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

      SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

      11/17/23 11:32:52 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

      SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

      11/6/23 11:35:23 AM ET
      $SONN
      Biotechnology: Pharmaceutical Preparations
      Health Care